Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SG001 plus pegylated liposomal doxorubicin in platinum-resistant recurrent epithelial ovarian cancer
CTR20211652Phase 2Active
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jul 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of PBI-1308, doxorubicin in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by CSPC ZhongQi Pharmaceutical Technology. Started Jul 2021; status: active.
02
Drugs
PBI-1308doxorubicin
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on CTR20211652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211652.